PhRMA Fears 'Potentially Limitless' State Suits After Risperdal Case
This article was originally published in The Pink Sheet Daily
Executive Summary
US Supreme Court denies J&J petition seeking review of South Carolina’s $124m judgment related to Risperdal marketing, giving state unfair trade practice laws a boost.
You may also be interested in...
Patent Settlements Stir Supreme Court Interest During Slow Term For Pharma Cases
High court seeks Solicitor General's view on whether patent settlements blocking authorized generics are anticompetitive; court denies GSK petition challenging payer claims in Avandia litigation.
Patent Settlements Stir Supreme Court Interest During Slow Term For Pharma Cases
High court seeks Solicitor General's view on whether patent settlements blocking authorized generics are anticompetitive; court denies GSK petition challenging payer claims in Avandia litigation.
Supreme Court Rejects Most Pharma Cases This Term, But Patent Settlements Stir Interest
High court seeks Solicitor General's view on whether patent settlements blocking authorized generics are anticompetitive; court denies GSK petition challenging payer claims in Avandia litigation.